Close Menu

Link Technologies

The company will integrate the oligonucleotide manufacturer with two of its existing sections to form a new Nucleic Acid Chemistry business unit.

The reagent supplier now has three Japanese distributors following a 2013 deal with GeneDesign as a representative throughout that country.

NEW YORK (GenomeWeb News) – Following its first distribution deal for Asia, Link Technologies today announced another deal covering that region, this time with Japanese firm GeneDesign

NEW YORK (GenomeWeb News) – Link Technologies today announced that it has signed on Zirench Technology to be its distributor in China.

NEW YORK (GenomeWeb News) – Link Technologies today announced a deal with American International Chemical for the distribution of some Link products in North America.

Under the terms of the agreement, Link will manufacture and sell diagnostic reagents based on the so-called exciplex technology, which is able to reduce the background fluorescent signal in nucleic acid assays in order to improve the detection sensitivity.

The company will make and sell a Manchester-developed diagnostic reagent technology through an agreement that includes a research collaboration.

Link will make and market reagents using RiboTask's UNA monomer technology.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.